Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform

Table 4

Different cell derivatives loaded with varied cargos for cancer diagnosis and therapy.

Refs.	Cell type	Loading method	Drugs/NPs	Drug/NP size (nm)	Cancer type	In vivo/in vitro
[32]	NK membrane	Coating	Gadolinium/PLGA NPs	109	Breast cancer	In vivo
[79]	MO membrane	Coating	Silicon particles	3200	Melanoma	In vivo
[80]	MA membrane	Coating	Dox/IND/Ce6/PEG/bilirubin complex	107	Breast cancer/melanoma	In vivo
[81]	MA membrane	Coating	PTX-albumin NPs	138.7	Melanoma	In vivo
[82]	MA membrane	Coating	Dexamethasone	N/A	Inflamed ear	In vivo
[83]	RBC membrane	Coating	Dox/Kirenol/phosphorous quantum dots	10	Cervical cancer	In vivo
[86]	Tumor cell membrane	Coating	AuNPs	40	N/A	In vitro
[22]	RBC sEVs	Encaps.	Free clodronate	N/A	CD47^-/-model	In vivo
[95]	Blood sEVs	Between lipid layers	Free Dox	N/A	Liver cancer	In vivo
[96]	T cell sEVs	N/A	Chimeric antigen receptor	N/A	Breast cancer	In vivo
[101]	Tumor cell sEVs	Encaps.	ZnO nanocrystals	91	KB cancer	In vitro
[102]	Blood sEVs	Both	Dox/miRNA21 inhibitor (in), MTf/L17E (on EVs)	106	Glioblastoma	In vivo
[103]	RBC sEVs	Encaps.	RNA	N/A	Breast cancer	In vivo
[104]	Cancer sEVs	Encaps.	Free methotrexate	N/A	CCA	In vivo
[87]	Artificial RBC	Encaps.	Hemoglobin-dopamine complex	100	Breast cancer	In vivo

Encaps. = encapsulation; BP = backpack. For other abbreviations, please refer to the abbreviation list.